Inc (NASDAQ:HUGE) () BioSciences Division President Dr Ed Brennan tells Proactive the company has begun a Phase 1 human study of its anti-inflammatory ultra-micronized-palmitoylethanolamide (PEA) after winning approval from the Ethics Committee of the Alfred Hospital in Victoria, Australia.
Dr Brennan says the drug has a broad application as an anti-inflammatory, where FSD where initially will be looking at pain and chronic pain indications.
CSE:HUGE
Market: CSE
Market Cap: $38.12 m
Follow
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of FSD Pharma named herein, including the promotion by the Company of FSD Pharma in any Content on the Site, the Company receives from said issuer...
FOR OUR FULL DISCLAIMER CLICK HEREDeep dive
FSD Pharma is building a mammoth hydroponic indoor cannabis production...
Most read
Full interview: FSD Pharma rings the bell to open trading day on the...
FSD Pharma (CSE: HUGE-NASDAQ: HUGE) Executive Co-Chairman and CEO Dr Raza Bokhari joined Steve Darling from Proactive Vancouver to talk about the company ringing the bell to open the trading day on the CSE. Dr Bokhari also discussed their phase 1 first-in-human safety and tolerability...
6 days, 5 hours ago
2 min read
Prev article
2 min read